The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography

Creative Commons License

UZLU D., Kose B., AKYOL N., ERDÖL H., GÜNAY M.

INTERNATIONAL OPHTHALMOLOGY, cilt.42, sa.7, ss.2107-2116, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42 Sayı: 7
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s10792-021-02209-x
  • Dergi Adı: INTERNATIONAL OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2107-2116
  • Anahtar Kelimeler: Uveitis, Refractory uveitis, Adalimumab, Fluorescein angiography, OCT, OPTICAL COHERENCE TOMOGRAPHY, LONG-TERM EFFICACY, BEHCETS-DISEASE, TNF-ALPHA, MULTICENTER, INFLIXIMAB, CORTICOSTEROIDS, STANDARDIZATION
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Aim To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography. Methods Twenty-three patients with refractory uveitis were included in study. Results Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91 +/- 3.78 (5-21) in baseline, 7.3 +/- 4.25 at third and 8.0 +/- 4.71 at sixth month (p = 0.022). The mean choroidal thickness was 256.65 +/- 43.63 mu m in baseline, 240.49 +/- 36.73 mu m at third and 224.81 +/- 34.91 mu m at sixth month (p <= 0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95 +/- 4.55 clock hours, 2.41 +/- 3.91 at third and 1.76 +/- 3.44 at sixth month (p < 0.001). Conclusion Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.